Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Iyer

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Journal of Medical Economics|April 24, 2015
Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosisSander Yermakov, Matthew Davis, Michaela Calnan, et al.
Therapeutic Advances in Psychopharmacology|October 6, 2025
Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trialSally Meikle, Olivia Carter, Paul Liknaitzky, et al.
Annals of the New York Academy of Sciences|August 21, 2025
Ranking by engagement and non-engagement signals: Learnings from industryTom Cunningham, Sana Pandey, Leif Sigerson, et al.
Annals of the New York Academy of Sciences|May 16, 2025
Social media harm abatement: Mechanisms for transparent public health assessmentNathaniel Lubin, Yuning Liu, Amanda Yarnell, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 21, 2008
Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemiaAnnalisa Lembo, Mark Pelletier, Ravi Iyer, et al.
The Lancet. Psychiatry|June 12, 2025
Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in AustraliaDan Siskind, Andrea Baker, Urska Arnautovska, et al.
Molecular & Cellular Proteomics : MCP|June 10, 2010
Protein analysis of purified respiratory syncytial virus particles reveals an important role for heat shock protein 90 in virus particle assemblyAnuradha Radhakrishnan, Dawn Yeo, Gaie Brown, et al.
Frontiers in Immunology|March 25, 2026
Structure and immunological activity of QS-21 variant from <i>Quillaja saponaria</i> aerial biomassRicardo San Martín, Yuzhong Liu, Yihan Yang, et al.
BMC Complementary Medicine and Therapies|February 24, 2026
The Silexan in the Treatment Of Posttraumatic stress disorder (STOP) trial: protocol for a 12-week randomised controlled trial of adjunctive Silexan for PTSDGreg Roebuck, Georgia M Parkin, Meaghan O'Donnell, et al.
Bjpsych Open|October 3, 2024
Protocol for Cancloz: multicentre randomised, placebo-controlled, double-blind, parallel-group adaptive trial of cannabidiol for clozapine-resistant schizophreniaDan Siskind, Claudia Bull, Shuichi Suetani, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Journal of Medical Economics|April 24, 2015
Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosisSander Yermakov, Matthew Davis, Michaela Calnan, et al.
Therapeutic Advances in Psychopharmacology|October 6, 2025
Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trialSally Meikle, Olivia Carter, Paul Liknaitzky, et al.
Annals of the New York Academy of Sciences|August 21, 2025
Ranking by engagement and non-engagement signals: Learnings from industryTom Cunningham, Sana Pandey, Leif Sigerson, et al.
Annals of the New York Academy of Sciences|May 16, 2025
Social media harm abatement: Mechanisms for transparent public health assessmentNathaniel Lubin, Yuning Liu, Amanda Yarnell, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 21, 2008
Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemiaAnnalisa Lembo, Mark Pelletier, Ravi Iyer, et al.
The Lancet. Psychiatry|June 12, 2025
Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in AustraliaDan Siskind, Andrea Baker, Urska Arnautovska, et al.
Molecular & Cellular Proteomics : MCP|June 10, 2010
Protein analysis of purified respiratory syncytial virus particles reveals an important role for heat shock protein 90 in virus particle assemblyAnuradha Radhakrishnan, Dawn Yeo, Gaie Brown, et al.
Frontiers in Immunology|March 25, 2026
Structure and immunological activity of QS-21 variant from <i>Quillaja saponaria</i> aerial biomassRicardo San Martín, Yuzhong Liu, Yihan Yang, et al.
BMC Complementary Medicine and Therapies|February 24, 2026
The Silexan in the Treatment Of Posttraumatic stress disorder (STOP) trial: protocol for a 12-week randomised controlled trial of adjunctive Silexan for PTSDGreg Roebuck, Georgia M Parkin, Meaghan O'Donnell, et al.
Bjpsych Open|October 3, 2024
Protocol for Cancloz: multicentre randomised, placebo-controlled, double-blind, parallel-group adaptive trial of cannabidiol for clozapine-resistant schizophreniaDan Siskind, Claudia Bull, Shuichi Suetani, et al.
Pageof 6